No
|
Ohshima category*
|
Histo
|
Sex
|
Ethnicity
|
Age (yrs)
|
Tissue type
|
GEP
|
HLH
|
Treatment
|
Follow up
|
OS (mth)
|
---|
1
|
A1
|
P
|
M
|
Indonesian
|
3.4
|
BM
|
No
|
+
|
HLH -P
|
Alive
|
55
|
2
|
A1
|
P
|
M
|
Chinese
|
13.1
|
BM
|
No
|
+
|
HLH-P, AHCT
|
Dead (AHCT complications)
|
48
|
3
|
A1
|
P
|
M
|
Vietnamese
|
24.8
|
BM
|
No
|
+
|
Chemo
|
Alive
|
6
|
4
|
A2
|
P
|
F
|
Chinese
|
5.3
|
BM
|
No
|
+
|
HLH-P, AHCT
|
Alive
|
64
|
5
|
A2
|
P
|
M
|
Chinese
|
1.4
|
Skin
|
Yes
|
+
|
HLH-P , AHCT
|
Alive (graft rejection)
|
95
|
6
|
A2
|
P
|
F
|
Indonesian
|
6.1
|
BM
|
No
|
+
|
HLH-P
|
Alive
|
31
|
7
|
A2
|
P
|
M
|
Chinese
|
16.7
|
LN
|
Yes
|
-
|
Steroids, AHCT
|
Dead
|
14
|
8
|
A1 or A2
|
P
|
M
|
Japanese
|
4
|
liver
|
No
|
+
|
AHCT
|
Alive
|
94.4
|
9
|
A1 or A2
|
P
|
F
|
Japanese
|
19
|
BM
|
No
|
-
|
AHCT
|
Alive
|
9.2
|
10
|
A1 or A2
|
P
|
F
|
Japanese
|
19
|
BM
|
No
|
+
|
Chemo
|
Alive
|
32.5
|
11
|
A1 or A2
|
P
|
F
|
Japanese
|
39
|
Skin
|
No
|
-
|
Chemo
|
Dead
|
21.8
|
12
|
A3
|
M
|
F
|
Vietnamese
|
16.4
|
BM
|
No
|
+
|
HLH-P
|
Dead
|
0.4
|
13
|
A3
|
M
|
F
|
Chinese
|
4.8
|
BM
|
No
|
+
|
HLH-P
|
Alive
|
21
|
14
|
B
|
M
|
M
|
Indonesian
|
13.3
|
BM
|
No
|
+
|
HLH -P
|
Dead
|
0.83
|
15
|
B
|
M
|
M
|
Indonesian
|
20.9
|
BM
|
No
|
+
|
HLH -P
|
Dead
|
2
|
16
|
B
|
M
|
F
|
Chinese
|
9.5
|
LN
|
Yes
|
+
|
Supportive
|
Dead
|
1
|
17
|
B
|
M
|
M
|
Chinese
|
18.7
|
LN
|
Yes
|
+
|
HLH -P
|
Dead
|
1.16
|
18
|
B
|
M
|
M
|
Vietnamese
|
1
|
BM
|
No
|
+
|
HLH-P
|
NA
|
NA
|
19
|
B
|
M
|
M
|
Filipino
|
7.6
|
BM
|
No
|
+
|
HLH-P
|
Dead
|
1
|
20
|
B
|
M
|
F
|
Chinese
|
19.3
|
BM
|
No
|
+
|
HLH-P
|
Dead
|
0.1
|
21
|
B
|
M
|
F
|
Japanese
|
48
|
BM
|
No
|
+
|
Chemo, AHCT
|
Dead
|
2.2
|
22
|
A3 or B
|
M
|
M
|
Others
|
18.3
|
BM
|
No
|
NA
|
Supportive
|
Dead
|
0.7
|
- Abbreviations: M male, F female, Histo histology, P polymorphic, M monomorphic, HLH-P 2004 Histiocytic Lymphohistiocytosis protocol, AHCT Allogeneic hematopoietic cell transplant, + present, − absent, TCR Clonality for TCRG gene, R rearranged, NR not rearranged, NA not available, OS overall survival, LN lymph node, BM bone marrow, Chemo chemotherapy. *Categorization of EBV-associated T/NK LPD in children proposed by Ohshima et al. [13].